“Biological Safety Testing Market Report is set to have rapid growth due high investments in biotechnology, increasing adoption in cancer research and development and increasing number of R&D investments at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biological Safety Testing Market Report: By Product, By Application (Vaccines & Therapeutics, Gene Therapy, Stem Cell), By Test, By Region, And Segment Forecasts

The global Biological Safety Testing market is poised for rapid growth between 2019 and 2029. Some factors that are driving market growth include growth in the pharmaceutical and biotechnology industries along with increasing investments and increasing production of new organic products due to the high burden of disease.

The increased need for Biologic products has led to unprecedented growth in the number of biopharmaceutical companies. This growing competition for the development of large-scale therapeutically advanced drugs has forced manufacturers to improve aspects such as productivity, cost efficiency and deviations. Companies are therefore implementing good manufacturing practices that involve thorough biological testing at various levels of production cycles, thus contributing to market growth.

In addition, increasing number of government initiatives to promote biological safety testing products are expected to drive overall market growth in the coming years. High rates of microbial contamination and biological burden during pharmaceutical and biological production should guide government and private organizations to improve underlying biological safety practices.

Leading companies featured in the report include Charles River Laboratories, Lonza Group, Merck Millipore, Wuxi PharmaTech, Avance Biosciences, Cytovance Biologics, Promega Corporation, Thermo Fisher Scientific, Toxikon and Eurofins Scientific

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.

11 January 2021

Read

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever